What Is Ensysce Biosciences, Inc. (ENSC) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Ensysce Biosciences, Inc. at $0.29. With an estimated intrinsic value of $0.62 and 6 of 9 models pointing higher, the average implied return is +112.5%. The most optimistic model, Dynamic NAV, places fair value at $1.49 (+410.6%), while ML-RIV — the most conservative — estimates $0.01 (-96.0%). This +506.6% gap reflects genuine analytical uncertainty about Ensysce Biosciences, Inc.'s intrinsic worth.
What Do the Models Say About ENSC?
9 of 13 models are currently active for ENSC. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates ENSC's intrinsic value at $0.10, implying -66.0% downside from the current price. See which stocks rank higher →
How Does ENSC Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ENSC ranks #273 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Ensysce Biosciences, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ENSC a Value Trap?
CirclFi's Value Trap algorithm assigns ENSC a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Ensysce Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Ensysce Biosciences, Inc. is rated at 4.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +506.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ENSC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ENSC's 9 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad